Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models. However, continuous exposure to NAMPT inhibitors, such as FK866, can induce acquired resistance.
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA / Thongon, Natthakan; Zucal, Chiara; D'Agostino, Vito Giuseppe; Tebaldi, Toma; Ravera, Silvia; Zamporlini, Federica; Piacente, Francesco; Moschoi, Ruxanda; Raffaelli, Nadia; Quattrone, Alessandro; Nencioni, Alessio; Peyron, Jean-Francois; Provenzani, Alessandro. - In: CANCER & METABOLISM. - ISSN 2049-3002. - 6:1(2018), p. 1. [10.1186/s40170-018-0174-7]
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA
Zamporlini, Federica;Raffaelli, Nadia;
2018-01-01
Abstract
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models. However, continuous exposure to NAMPT inhibitors, such as FK866, can induce acquired resistance.| File | Dimensione | Formato | |
|---|---|---|---|
|
unpaywall-bitstream-1447078661.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Creative commons
Dimensione
4.78 MB
Formato
Adobe PDF
|
4.78 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
